Patients

Five things for pharma marketers to know: Wednesday, March 22, 2017

Five things for pharma marketers to know: Wednesday, March 22, 2017

By

Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD

New healthcare bill to negatively affect drugmakers: Moody's

New healthcare bill to negatively affect drugmakers: Moody's

By

Per the credit ratings agency, more uninsured Americans will lead to less demand for healthcare services and treatments.

From SXSW: Learnings for Healthcare Marketers from the NYT and WWE

From SXSW: Learnings for Healthcare Marketers from the NYT and WWE

As we build health solutions, making decisions in office parks and around conference tables, it's easy to lose the individual person through the scale of our work.

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

In short, he'll be further along the learning curve than anyone ever tapped for the nation's number-one public health regulatory slot.

Five things for pharma marketers to know: Wednesday, March 15, 2017

Five things for pharma marketers to know: Wednesday, March 15, 2017

By

The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits

Klara's Simon Lorenz on breaking away from the physician lifestyle

Klara's Simon Lorenz on breaking away from the physician lifestyle

By

He instead decided to find a way to make a physician's job easier by creating a clinical messaging platform.

Infographic: What's next for the point of care market

Infographic: What's next for the point of care market

About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.

Five things for pharma marketers to know: Monday, February 27, 2017

Five things for pharma marketers to know: Monday, February 27, 2017

By

Pfizer receives subpoena over patient assistance programs; drugmakers raise prices less this January than last; lawmakers have new plan to repeal ACA

Predicting Patient Behavior Improves the Brand Message

Predicting Patient Behavior Improves the Brand Message

Few questions give healthcare marketers more heart palpitations than this one: "How do you know it will work?"

Top 25 rare disease brands, by sales

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

Genentech Should Let Us See Its Herceptin Documentary

Genentech Should Let Us See Its Herceptin Documentary

By

The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.

Marketers take a new approach to lung-cancer campaigns, and why that matters

Marketers take a new approach to lung-cancer campaigns, and why that matters

By

Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.

Five things for pharma marketers to know: Tuesday, January 31, 2017

Five things for pharma marketers to know: Tuesday, January 31, 2017

By

Diabetes patients sue drugmakers over price increases; the FTC opens Mylan investigation; Fitbit to ramp up marketing

Giant's Kristina Ellis Highlights 6 Campaigns that Create Empathy

Giant's Kristina Ellis Highlights 6 Campaigns that Create Empathy

Here are six creative campaigns that use creativity to connect with the audience.

For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

By

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

Five things for pharma marketers to know: Thursday, December 29, 2016

Five things for pharma marketers to know: Thursday, December 29, 2016

By

Gilead forms network to encourage access to hep.-C drugs; Dentsu CEO to resign following the suicide of a staffer; BI to divest animal-health products

Five things for pharma marketers to know: Tuesday, December 27, 2016

Five things for pharma marketers to know: Tuesday, December 27, 2016

By

Allergan's board endorses its social contract with patients; drugmakers that market painkillers are hiring DEA officials; the FDA approves new Biogen drug

The doctor-patient dialogue: As productive as it's ever been or broken?

The doctor-patient dialogue: As productive as it's ever been or broken?

By

More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.

30 years later, DTC's complicated past still hasn't deterred marketers

30 years later, DTC's complicated past still hasn't deterred marketers

By

Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.

Five things for pharma marketers to know: Thursday, September 29, 2016

Five things for pharma marketers to know: Thursday, September 29, 2016

By

Sharecare acquires virtual-reality developer; Novo Nordisk to cut 1,000 jobs; the FDA approves Medtronic's automated insulin pump

Why Any Merger is the Last Resort of Lousy Marketers

Why Any Merger is the Last Resort of Lousy Marketers

By

Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?

Discovering Meaningful Insights in Patient Journeys: Identifying Hidden Patterns Using Advanced Analytics

Discovering Meaningful Insights in Patient Journeys: Identifying Hidden Patterns Using Advanced Analytics

During this seminar, attendees will learn how advanced data analytics can be applied to gain a measurable competitive advantage.

Adherence: Leveraging Data to Enhance Your Brand's Ability to Reach Target Patients

Adherence: Leveraging Data to Enhance Your Brand's Ability to Reach Target Patients

In this webcast, TrialCard VP of analytic services Paul LeVine and senior analytic consultant Robert Leedom underscore how affordability programs provide the ideal venue for focusing on adherence issues.

Podcast: Adherence: Leveraging Data to Enhance Your Brand's Ability to Reach Target Patients

Podcast: Adherence: Leveraging Data to Enhance Your Brand's Ability to Reach Target Patients

In this sponsored podcast, MM&M's Larry Dobrow speaks with Robert Leedom, senior analytics consultant at TrialCard, and Paul LeVine, VP of analytic services for TrialCard, about how to reach patients by leveraging brand data.

Sex, chocolate, and disability: What marketers can learn from Mars' Maltesers campaign

Sex, chocolate, and disability: What marketers can learn from Mars' Maltesers campaign

By

The latest TV campaign from Mars features a woman with cerebral palsy joking about her love life.

Infographic: How physicians share online info with patients and other docs

Infographic: How physicians share online info with patients and other docs

The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

By

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

How Insights from Patients Can Shape Medical Practice and Communication

How Insights from Patients Can Shape Medical Practice and Communication

Many patients find it difficult to ask questions of their physician.

Patient-Centricity: There's Always Room for Improvement

Patient-Centricity: There's Always Room for Improvement

It's unlikely that pharma will ever achieve the degree of consumer love directed at Amazon and Apple but the shift taking place will open up doors for pharma organizations.

Hacking Healthcare: Will It Help the Patient?

Hacking Healthcare: Will It Help the Patient?

The power of hackathons is now magnified because of the power of the internet and social media, giving both patients and healthcare professionals a global platform for their voices.

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters